OPM Biosciences (Stock Code: 688293) is a leading provider of Cell Culture Media (CCM) and CDMO (Contract Development and Manufacturing Organization) services. We offer an integrated solution to meet the needs of biopharmaceutical companies worldwide. OPM was established in 2013 dedicated to total cell culture solution development, which has resulted in our fast growth. We are proud to be the first listed CCM company in China and committed to being a total solution provider in biologics development. Our management system is certified to ISO9001:2015 by TÜV NORD. We have four fully cGMP-compliant plants, covering an overall area of 18,000m². Currently, we are constructing a new 30,000m² headquarters to meet the growing demand for our products and services. OPM is becoming a strategic partner of biopharmaceutical companies worldwide, and our dedication to quality and innovation ensures that we continue to be a trusted partner in the industry. Our CCM solutions are renowned for their innovative chemically-defined/serum-free media design and manufacturing. We offer a range of products and services, including proprietary commercial media, customized formulations, and OEM solutions for our clients’ unique cell lines. Our exceptional performance has established us as the preferred supplier for over 230 biologics (IND or BLA) worldwide. In addition, OPM’s CDMO services provide efficient End-to-End solutions for biotherapeutic protein development and manufacturing. Our cGMP-compliant facilities support all stages of biologics development, from antibody discovery to IND and BLA manufacturing up to 2000L. Our dedicated team of experienced scientists is committed to excellence and has contributed to the development of over 200 biologics, supporting global clients in achieving successful IND applications with the FDA and NMPA.
SEKISUI
BioProduction by SEKISUI describes SEKISUI’s contract service offering as a microbial focused CDMO with expertise in proteins and downstream purification. Our fermentation process development and production experience helps smooth technical transfer and process scale up. Our core competencies include E.coli and yeast fermentation, plant protein extraction, large scale bioprocessing, protein purification, bulk formulation, lyophilization and analytical testing. Our production site in the UK has been a leader in the manufacturing of high-quality proteins and specialty biochemicals globally to the healthcare market for over 40 years. We have worked with many global partners to supply high quality materials for a variety of applications, including proteins for biotherapeutics, pharmaceuticals, and diagnostic medical devices. | SEKISUI Medical Group is a diverse, global network consisting of a diagnostics business and pharmaceutical sciences business which spans drug development services and manufacturing, including active pharmaceutical ingredients and pharmaceutical intermediates, amino acids, as well as a wide range of enzymes for use in diagnostics, and biopharmaceutical contract manufacturing and more BioProduction by SEKISUI is a trusted provider of specialized CDMO services, offering biomanufacturing solutions built on decades of experience in microbial fermentation and downstream processing. We support the full development lifecycle—from strain optimization to clinical-scale manufacturing—catering to a wide range of biologics including enzymes, recombinant proteins, antibody fragments, viral vectors, and plasmids. Our microbial expertise spans multiple expression platforms including E. coli, Pichia pastoris, Bacillus, Streptomyces, Streptococcus, fungi, and yeast, enabling highly flexible and efficient process development for biologics. Our advanced UK facility based in Kent is equipped for full spectrum biomanufacturing services and features: Fermentation capacity from 2 L R&D scale up to 5,000 L production Integrated protein expression services for high-yield production Advanced chromatography and purification suites End-to-end antibody production services Lyophilization and bulk formulation GMP-aligned systems under ISO 9001 and ISO 8 cleanroom classifications In-progress GMP plasmid manufacturing and clinical-grade expansion Environmental control and zero-emissions sustainability framework We also provide expert plasmid production for research and therapeutics, with growing capabilities in viral vector manufacturing for cell and gene therapy markets. As established recombinant protein manufacturers, we support custom expression and scale-up for diverse biopharmaceutical programs. In cell and gene therapy, SEKISUI is committed to enhancing the reliability, scalability, and efficiency of cell culture. Ceglu™, our lead technology, is a chemically defined, synthetic matrix that provides a stable, feeder-free environment for culturing stem cells (iPSCs, ESCs, MSCs). To accommodate diverse workflows, Ceglu™ is available in two formats: ready‑to‑use pre‑coated culture ware for research workflows, and an automation‑friendly coating solution for cell manufacturing workflows which can be precoated and sterilized onto closed systems or bioreactor consumables for seamless cell production. With a focus on advancing regenerative medicine, SEKISUI partners with service providers, biopharma organizations, bioprocessing innovators and academia to deliver solutions that meet the evolving needs of the industry. Drop by our booth 5621 to ask us about our GMP-readiness, room temperature storage and iPSC.
Richter BioLogics GmbH
Richter BioLogics stands at the forefront of Germany’s contract development and manufacturing sphere, with a specialized focus on products derived from bacteria and yeasts. Our three facilities boast capacities of 2 x 1,500L and 2 x 300L, facilitating the production of plasmid DNA, antibodies, including VHH/nanobodies, proteins, and vaccines. With over 35 years of proven success, our highly skilled teams are dedicated to supporting clients through every stage of production. We offer robust process development, supply products for clinical trials, oversee commercial production, conduct in-house quality control testing, and provide QP release. Our commitment to excellence is reflected in our adherence to the highest pharmaceutical quality standards, as verified by major regulatory bodies such as EMA, FDA, ANVISA, PMDA, and MFDS, alongside numerous customer audits. At Richter BioLogics, we pride ourselves on delivering reliable solutions with precision and expertise, ensuring our partners achieve their clinical and commercial goals with confidence. | Richter BioLogics stands at the forefront of contract development and manufacturing (CDMO) sphere, with a specialized focus on products derived from bacteria and yeasts. Our three facilities boast capacities of 2 x 1,500L and 2 x 300L, facilitating the production of antibodies, including VHH/Nanobodies, proteins, vaccines and plasmid DNA. With over 35 years of proven success, our highly skilled teams are dedicated to supporting clients through every stage of production. We offer robust process development, supply products for clinical trials, commercial production, conduct in-house quality control testing, and provide QP release. Our commitment to excellence is reflected in our adherence to the highest pharmaceutical quality standards, as verified by major regulatory bodies such as EMA, FDA, ANVISA, PMDA, and MFDS, alongside numerous customer audits. At Richter BioLogics, we pride ourselves on delivering reliable solutions with precision and expertise, ensuring our partners achieve their clinical and commercial goals with confidence and in time.
Pyramid Labs
SFF CDMO Aseptic Fill/Finish Services. Vial and Syringe Filling Lyophilization Analytical Services In-house Bioburden & Sterility Clinical & Commercial Manufacturing Stability Services Clinical & Commercial Labeling Breakloose/Glide Force testing. PPQ High Recovery Vials HRV US based manufacturing sites Drug Product CMC 510k Biologics mAb oligonucleotides peptides small molecules siRna nanoparticles Parenteral filling | Pyramid Pharma Services is a U.S.-based clinical-to-commercial fill-finish CDMO with over 26 years of GMP drug product manufacturing experience and more than 35 years in business. We provide aseptic manufacturing and sterile manufacturing solutions for complex injectable drug products, supporting both emerging biotech and established pharmaceutical companies. Our expertise includes oligonucleotides, peptides, biologics, and advanced therapeutics, with integrated capabilities that span formulation development, aseptic fill-finish, lyophilization, prefilled syringe and cartridge filling, device assembly, labeling, packaging, and analytical services. By offering end-to-end drug product manufacturing within a single organization, we reduce complexity, accelerate timelines, and ensure consistent execution from clinical development through commercial supply. Pyramid’s California-based facilities support flexible manufacturing across a range of batch sizes and delivery formats, including vials, prefilled syringes, and cartridges. Ongoing investment in advanced, high-speed fill-finish infrastructure strengthens our ability to deliver scalable, reliable solutions for increasingly complex injectable therapies. Our track record includes over 100 successful IND-enabling programs, multiple commercial products, and a strong history of FDA inspections—demonstrating a consistent focus on quality, compliance, and execution. As a fill-finish CDMO, we partner closely with our clients’ CMC, technical, and regulatory teams to support efficient development and commercialization. We work with companies developing injectable therapies that require a reliable, experienced partner for sterile fill-finish and aseptic drug product manufacturing. If you are advancing a program and evaluating a CDMO for fill-finish or drug product manufacturing, we welcome the opportunity to connect at BIO 2026. Schedule time with our team to discuss your program.
PSC Biotech
Founded in 1996, PSC Biotech Corporation is a global organization that has spent over two decades providing life science services and solutions through our professional service consultancy for CQV, CSV, auditing, IT services, and much more. PSC Software provides inspection/audit management and eQMS services and BioTechnique provides CRDMO services. We also distribute equipment (Lives International data loggers and thermal mapping systems). Since its inception, PSC has served as a strategic partner to emerging and established life science companies, helping them bring their life-saving products to market. | PSC Biotech® is a global specialty life sciences consultancy firms, supporting over 1000 clients in more than 35 countries. PSC Biotech Corporation® provides life science services and solutions through our professional service consultancy (CQV, CSA/CSV, Audit, and much more.) PSC Software® provides inspection management and electronic quality management systems that enable businesses to stay compliant while effectively and efficiently delivering products to market. PSC Software® has 4 proprietary, 21 CFR Part 11 compliant, cloud-based systems that accelerate and streamline quality processes. BioTechnique® is a division of PSC Biotech Corporation®. BioTechnique® is a Contract Research, Development, and Manufacturing Organization (CRDMO) that provides lyophilization and therapeutic sterile injectable fill-finish solutions to cater to both large and small investigational/clinical stage or commercial batch sizes. BioTechnique® provides a comprehensive platform for success, beginning with Formulation Studies, extending through Analytical and Formulation Development, and culminating in Product Launch (clinical or commercial). | . | BioTechnique is a CRDMO, pharmaceutical manufacturing facility located in York, PA. A highly potent sterile injectable and clinical oncolytics manufacturing company dedicated to providing cytotoxic and high potency sterile injectable fill-finish services. Our project management and client services staff work closely with clients to meet all their manufacturing needs. We provide formulation and compounding, fill-finish, lyophilization, shipping, storage, and 3rd party logistics for a wide variety of liquid injectables. BioTechnique utilizes our expertise to create process designs for client product needs. To learn more, visit www.biotechnique.com
ProJect Pharmaceutics (PJP)
PJP is the go-to specialist in formulation and process development across complex biologics, bioconjugates, and other therapeutic modalities. Our development agility spans liquid, frozen, and lyo formats in vials, cartridges, or pre-filled syringes and in-step or independent from your chosen manufacturer. Let’s solve your formulation and process challenges together.
Polish Investment & Trade Agency
The Polish Investment and Trade Agency is a mission driven, government entity, that is dedicated to promoting and growing the economy of Poland on a global stage. Anchored in Warsaw, with a network of nearly 60 foreign trade offices around the world, the Agency’s mission is to increase the awareness of Polish brands in international markets and to promote national products and services. This mission is accomplished by three pillars: promoting Polish exports, supporting the inflow of foreign direct investments to Poland and the implementation of Polish investments in the country, and the cultivation of partnerships with domestic and international stakeholders. | . | The Polish Investment and Trade Agency (PAIH) is Poland’s leading government agency dedicated to promoting Polish business on the international stage and attracting foreign investment to Poland. As a key partner for international companies looking to explore opportunities in Poland, PAIH provides comprehensive support to exporters and investors, bridging connections between global markets and the dynamic Polish economy. At the BIO International Convention, PAIH proudly coordinates the Polish National Pavilion, a platform showcasing Poland’s innovation potential in the life sciences sector. In collaboration with BioForum Central European Life Science Cluster, this year’s booth features 26 outstanding Polish companies representing the strength, diversity, and international ambitions of Poland’s biotech ecosystem. At this year’s BIO International Convention, Polish exhibitors will present cutting-edge solutions across four key categories: Drug Development, Diagnostics, Manufacturing, and Digital Solutions and Services. We invite all BIO International Convention participants to visit the Polish National Booth, meet our innovative companies, and explore partnership opportunities across the biotech value chain—from early-stage research and diagnostics to digital transformation and advanced manufacturing. | xxxx
PlasmidFactory GmbH
PlasmidFactory GmbH, established in 2000 in Bielefeld, Germany, is a premier contract development and manufacturing organization specializing in plasmid and minicircle DNA. We support clients and partners in cancer research, gene and cell therapy, and vaccination, with a focus on CAR-T cell development, AAV gene transfer, and minicircle tools for mRNA synthesis. We offer custom plasmid and minicircle DNA manufacturing services across various quality grades from Research and CCC grade up to High Quality grade and GMP certified material for clinical trials and applications. Our state-of-the-art facilities fulfil the highest quality standards, with full GMP services launching in Q4, 2025. Our extensive In-Stock product range supports immediate research needs, including AAV production plasmids and reporter constructs. At the forefront of Next Generation Gene Vectors, our R&D focuses on advancing our proprietary minicircle DNA technologies. Through strategic collaborations with global partners, we are committed to pioneering solutions for academia and the biopharmaceutical industry. – 25 years CDMO experience and innovation in plasmid and minicircle DNA – +3000 successful projects – From research grade to GMP – Talk to us to discuss how we can support your projects in the area of CGT, AAV or mRNA | PlasmidFactory GmbH, established in 2000 in Bielefeld, Germany, is a premier contract development and manufacturing organization specializing in plasmid and minicircle DNA. We support clients and partners in cancer research, gene and cell therapy, and vaccination, with a focus on CAR-T cell development, AAV gene transfer, and minicircle tools for mRNA synthesis. We offer custom plasmid and minicircle DNA manufacturing services across various quality grades from Research and CCC grade up to High Quality grade and GMP certified material for clinical trials and applications. Our state-of-the-art facilities fulfil the highest quality standards, with full GMP services launched in 2025. Our extensive In-Stock product range supports immediate research needs, including AAV production plasmids and reporter constructs. At the forefront of Next Generation Gene Vectors, our R&D focuses on advancing our proprietary minicircle DNA technologies. Through strategic collaborations with global partners, we are committed to pioneering solutions for academia and the biopharmaceutical industry. – 25 years CDMO experience and innovation in plasmid and minicircle DNA – +3000 successful projects – From research grade to GMP – Talk to us to discuss how we can support your projects in the area of CGT, AAV or mRNA
PharSafer
Founded in 2003 by Dr Graeme Ladds, PharSafer® is a specialist Contract Research Organisation (CRO) in Global Clinical and Post Marketing Drug Safety, and Medical Services, with a wealth of experience in Pharmacovigilance, Auditing and Medical Affairs – and the various, numerous and extensive legal safety/medical obligations for licence holders to comply with – as well as Regulatory Strategy for the best methods for obtaining scientific advice concerning licence submissions and approvals. Together with our sister company which focuses on Training: SaPhar, PharSafer® continuously seeks new and innovative ways to provide added value for our global clients – going above and beyond expectations and optimising processes and procedures involved with clinical and post marketing drug safety and licencing approach. Our ability to offer first-class services in Pharmacovigilance, Regulatory Affairs, Training, Auditing, Medical Affairs and IT Informatics means that, for many clients, we operate as their Pharmacovigilance and Medical Departments – guiding them through the labyrinth of drug safety and medical legislation, all in the interests of ensuring patient safety and client compliance. We love what we do. We love finding solutions. Quite simply, we are by far… Your leading partner in Drug Safety. | PharSafer is a Global CRO specialising in Clinical & Post Marketing Pharmacovigilance; Medical Affairs; Training; Auditing; IT Informatics and Regulatory Intelligence. PharSafer have been operating for the last 23 years growing annually and helping take Companies from their clinical to post-marketing phases and many clients have been with us over 10 years now. PharSafer have attended over 100 inspections on behalf of clients to aid their compliance and ensure Regulatory Authorities are satisfied with the activities being performed. PharSafer are also an innovative Company designing validated and automated systems to provide cost-effective solutions for clients and ensure Regulatory compliant systems. Our client base is truly global being in all continents and for clients that have drugs; devices; vaccines; biologics; advanced therapies; biosimilars; herbal and cosmetics. Our Team within the Company are very experienced (many with over 15 years experience) aided by our sister training Company (SaPhar) to provide new updates for clients on country specific regulations with regular monthly contacts and comments going to all clients. We would be happy to engage with you and talk about product development; product expansions into new countries; product launches and perform all of the activities mentioned above. Please review of website and we look forward to engaging with you personally.
Pharmadule Morimatsu
Pharmadule Morimatsu is a global leader in modular pharmaceutical and biopharma manufacturing facilities. Pioneering modular delivery since 1986 and part of the Morimatsu Group since 2011, we design, fabricate, and deliver turnkey modular plants—combining process equipment, cleanrooms, and full facility solutions—for the life sciences and consumer products industries. Key benefits: Fixed-price certainty Flexible, scalable modules Rapid deployment worldwide (80% off-site fabrication) Reduced risk in time, cost, and quality From vaccine plants to biotech facilities, we provide fast, reliable, regulatory-compliant solutions delivered anywhere in the world. | We are a world leader in the delivery of innovative modular facilities and process equipment solutions for Life Science Industry. Originally founded in Sweden in 1986, Pharmadule was acquired in 2011 and is now part of the Morimatsu Industrial Group. This strong combination has allowed us to combine process modularization with modular facilities to deliver our clients complete turnkey solutions.